The present invention relates generally to medical devices and methods. More particularly, the present invention relates to a therapy device having a deployable treatment needle with a plurality of tines deployable in a straight path from said needle.
Uterine fibroids are benign tumors in the uterine wall and are the most common tumor of the female pelvis. Fibroids afflict up to 30% of women of childbearing age and can cause significant symptoms including discomfort, pelvic pain, mennorhagia (excessive bleeding), anemia, infertility, and miscarriage. While fibroids may be located in the muscle (intramural), adjacent to the endometrium (submucosal), or in the outer layer of the uterus (subserosal), and can grow up to several centimeters in diameter.
Current treatments for fibroids include both pharmaceutical and surgical intervention. Pharmaceutical treatments include the administration of NSAIDS, estrogen-progesterone combinations, and the like. Medications, however, are generally ineffective and are palliative rather than curative. Surgical interventions include myomectomy, where fibroids are removed in an open surgical procedure requiring laparotomy and general anesthesia, and hysterectomy, involving complete surgical removal of the uterus. Both these procedures are long and have significant blood loss.
As improvements over open surgical procedures, several minimally invasive procedures have been developed. Laparoscopic myomectomy is a laparoscopic procedure requiring highly skilled laparoscopic gynecologists. Uterine artery embolization relies on blocking the uterine artery supplying blood to the fibroid by injecting small particles. While sometimes effective, common complications of arterial embolization include infection, premature menopause, and severe pelvic pain. A third approach relies on complete endometrial ablation, which is generally effective for treating bleeding but less reliable for treating fibroids.
More recently, and of particular interest to the present invention, the use of radiofrequency needles and other ablation elements for treating individual fibroids via a transvaginal approach has been proposed. As described, for example, in published U.S. Patent Applications 2006/0189972; 2007/0179380; 2007/0249936; and 2008/0033493, each of which is commonly assigned with the present application, a probe carrying a needle is used to treat individual fibroids. The probe carries on-board ultrasonic or other imaging so that the needle can be guided into the fibroid under direct observation.
While effective in many cases, the use of a single needle for treating fibroids and other solid tissue masses has certain shortcomings. In particular, the volume of tissue that can be treated by a single needle is limited. Even if large diameter needles are used, the surface area of the needle limits the amount of energy that can be imparted into the tissue and ultimately limits the distance from the needle that can be effectively treated.
To increase the effective volume that can be treated using a single needle deployment, the use of multiple, simultaneously deployed needles has been proposed. Of particular pertinence, U.S. Pat. No. 6,050,992 describes a system for deploying multiple everting needles from a single central cannula. In some instances, the needles can be deployed over an outwardly curving surface (see
For these reasons, it would be desirable to provide needle structures and deployment assemblies capable of deploying multiple needles, tines, or other components in order to increase the volume of tissue to which radiofrequency or other electrical energy can be delivered. It would be further desirable to provide such multiple needle delivery structures and deployment assemblies where the diameter, width, length, and other dimensions of the structure may be minimized. It would be still further desirable to provide such multiple needle deployment structures and deployment assemblies which have a reduced or minimized insertion force for advancement through solid tissue. It would be additionally desirable to provide a needle delivery structure in which placement of the needle or electrode is predictable. At least some of these objectives will be met by the inventions described hereinbelow.
The following US published applications discussed above are relevant to the present invention: 2006/0189972; 2007/0179380; 2007/0249936; and 2008/0033493. The disclosures of each of these applications is incorporated herein by reference. See also U.S. Pat. No. 6,050,992 and US 2007/0006215.
In a first aspect of the present invention, a needle electrode deployment shaft comprises a central member and a plurality of needle electrodes which are deployable from the central member. The central member will have a proximal end, a distal end, a longitudinal axis therebetween, an outer surface, and a plurality of needle electrode advancement channels therein, typically formed in the outer surface. Each channel will have an axially aligned proximal portion and an outwardly directed distal ramp portion such that as the needle electrodes are advanced through the channel, the needles will be deflected radially outwardly as they pass over the ramp so that they can enter the tissue in an outwardly diverging pattern. The ramp may be flat or curved, but will usually be curved as described in more detail below.
The individual needles may be elastic or malleable, where suitable malleable needles are formed from stainless steel, titanium, or tungsten, gold, silver, or other conventional malleable metals. Suitable elastic needles may be formed from spring stainless steels, shape memory alloys, such as nitinol, eligiloy, and the like. In preferred aspects, the needles will be elastic with a pre-shaped straight configuration so that the portion of the needle passing over the ramp will be reversibly deflected with the portion of the needle distal to the ramp returning back to a straight configuration. It is desirable to minimize residual strain after multiple deflection or bending cycles. Residual strain can be minimized by ensuring the electrode material is not appreciably stressed beyond its elastic limit. This allows for repeatable needle electrode placements, and, thus, repeatable treatment ablation volumes.
It will generally be desirable to deflect the advancing needles outwardly at a relatively large angle, typically from 20.degree. to 50.degree., preferably 25.degree. to 45.degree., relative to the axis of the central member, more preferably an angle such that the tissue is adequately ablated. While such angles of deflection could theoretically be obtained by providing relatively short, sharply angled ramps, such short, steeply deflected ramps will increase the stress imparted to the needles. By increasing the radial component of the lengths of the ramps, the exit angle of the needles relative to the axis of the central member is increased for a given stress level. The ability to increase the exit angle, for example, by lengthening the ramp, however, can be limited in certain designs, particularly designs having a relatively small diameter central member.
Therefore, in accordance with the principles of the present invention, ramps may be provided in the channels formed in the central member where the entrance to and exit from the ramp are angularly offset from each other. That is, the ramp entrance will be located at a first angular orientation relative to the longitudinal axis and at a pre-selected depth beneath the outer surface and the ramp exit will be located at a second angular orientation which is angularly offset from the first angular orientation. By angularly offsetting the entrance and exit of the ramp, the length of the ramp (including the radial component) through which the needle electrodes travel will be increased. By increasing the radial component of the ramp length, the stress imparted into individual needles can remain in the desired elastic strain limit while allowing a larger exit angle. By so doing, the needles may be deployed multiple times with predictable deployment placement.
The central member may be formed of a simple tube or cannula, but will more usually have a sharpened distal end which allows the central member to self-penetrate into tissue prior to deployment of the needle electrodes. The central member may be electrically passive or neutral (so that it does not itself act as an electrode) or may be electrically active, either being connected with the same (monopolar) or the opposite (bipolar) polarity as individual needle electrode(s). The individual needle electrodes may also be connected with a common polarity or different polarities, allowing for a variety of specific monopolar and bipolar needle configurations to be utilized. The needle electrode deployment shafts of the present invention will usually have from three to nine channels and from three to nine electrodes, preferably one electrode in each channel. The angular offset between the first angular orientation of the ramp entrance and second angular orientation of the ramp exit will preferably be in the range from 0.degree. to 180.degree., more preferably 45.degree. to 150.degree. The central member will typically have a diameter in the range from 0.75 mm to 3.1 mm and the pre-selected radial distance at the ramp entrance will be in the range from 0.25 mm to 1.25 mm. The axial distance between the ramp entrance and the ramp exit will usually be in the range from 2.5 mm to 25 mm.
As described above, the ramp entrance and the ramp exit will be angularly offset from one another, where such angular offset increases the distance between the entrance and exit relative to the distance if the entrance and exit had been axially aligned. The path between the angularly offset entrance and exit may itself be straight, but will more usually be curved, sometimes following a generally spiral pattern, as will be described in greater detail in connection with the drawings hereinafter.
The needle electrodes may have a variety of tip configurations, but will usually have a sharpened or other tip which is configured to permit self-penetration of the needle electrodes as they are advanced from the central member. In a preferred configuration, the needle electrodes will have a beveled end with a surface which is oriented so that it engages a surface of the ramp as the needle is advanced through the channel. The beveled end will thus reduce the friction and seizing which could occur if a sharpened edge of the needle were to be engaged against the ramp as the needle is advanced. The surface may be flat (planar), curved, multi-faceted, or otherwise configured to engage the ramp with minimum friction.
In another aspect of the present invention, the needle electrode deployment shafts and assemblies just described may be incorporated into a probe body, optionally together with an ultrasonic imaging array, in order to provide an imaging and therapeutic delivery system. The probe body will typically be able to penetrate solid tissue (usually having a self-penetrating tip and/or a passage for receiving a stylet), allowing deployment of both the needle electrodes and the ultrasonic imaging array from the probe body to treat fibroids or other tissue masses within solid tissue. Usually, the ultrasonic imaging array will be configured and positioned so that deployment of the needle electrodes from the deployment shaft may be monitored.
In a further aspect of the apparatus of the present invention, a needle electrode deployment shaft comprises a central member and a plurality of needle electrodes deployable from the central member. The central member has a proximal end, a distal end, a longitudinal axis therebetween, an outer surface, and a plurality of needle electrode advancement channels therein. Each channel has an axially aligned proximal portion and an outwardly directed distal portion.
In specific accordance with the present invention, the needle electrode deployment shafts may include a spike or other introducer tip having a sharpened tip which extends from the distal end of the central member. The spike will have a diameter which is less than that of the central member, typically being in a range from 20% to 95% of the diameter of the central member, preferably for 25% to 60%, and more preferably from 30% to 55%, where the reduced diameter spike reduces the insertion force required to advance the shaft into tissue (prior to subsequent deployment of the needle electrodes from the shaft). Such needle electrode deployment shafts will preferably further comprise a transition region between the spike and the central member, where the transition region may be conical, spherical, or have other geometric configurations. In some cases, the transition region may define a cutting edge to further facilitate advancement of the shaft into solid tissue.
In a still further aspect of the present invention, methods for treating uterine fibroids comprise introducing a probe into a uterus. An ultrasonic transducer carried by the probe is used to locate the uterine fibroid or other tissue mass to be treated. A needle deployment shaft is advanced from the probe in the uterine tissue proximate the uterine fibroid, and a plurality of needle electrodes are advanced from the deployment shaft into the uterine fibroid and/or tissue surrounding the uterine fibroid. The needles are advanced through an array of outwardly directed channels or ramps into the uterine fibroid and/or tissue surrounding the uterine fibroid, and energy is delivered from the needle electrodes to necrose the fibroid. Typically, the energy is radiofrequency energy, where the radiofrequency energy may be monopolar or bipolar.
In a further aspect of the present invention, a needle electrode deployment device comprises a central member having a proximal end, a distal end, and a pre-defined cross-sectional area. The central member will typically be cylindrical, and the cross-sectional area will be the area of the circular cross-section normal to the axis of the cylindrical central member. Other, non-circular cross sections may also be employed, and in certain cases, the central member could be tapered, typically with a reduced cross-sectional area nearer its distal end.
The needle electrode deployment device may further comprise a central electrode or needle having a tissue-penetrating distal end which is slidably received in an axially aligned central electrode advancement lumen or passage formed through the central member, usually extending fully from the proximal end to the distal end and terminating in an open electrode deployment port at the distal end. The device further comprises a spike or introducer tip extending distally from the distal end of the central member, where the spike has a cross-sectional area which is less than that of the central member, typically being less than one half of the cross-sectional area of the central member, typically being no more than 45% of the central member area, and more typically being no more than 40% of the central member area. The cross-sectional geometry of the spike or introducer tip may vary, but in all instances there will be a tissue-penetrating element or geometry provided at the distal end thereof. In the exemplary embodiments, the tissue-penetrating distal end is in the form of a sharpened, typically trocar-style tip so that the spike can be advanced into solid tissue followed by the central member. The tissue-penetrating spike will also have an axis, and in certain embodiments the axis of the spike will be parallel to but radially offset from the axis of the central member, typically having a radially outer surface aligned with the radially outer surface of the central member. The radially offset orientation of the spike or other introducer tip opens and provides access to the distal electrode deployment port of the electrode advancement passage so that the needle electrode can be axially advanced from the central member to follow a path which is parallel to that of the spike or other introducer tip.
Positioning of the introducer tip in “offset alignment” with the tissue-penetration path of the needle being advanced from the electrode advancement passage is advantageous since it reduces focal stress on the electrode by having its electrode advancement passage exit more proximal than the most distal portion of the introducer tip. After the device has been introduced into tissue, the central electrode can sometimes become misaligned due to movement of the device by the physician. By having the electrode deployment passage exit more proximal, the focal stress induced on the electrode by the introducer tip during retraction is reduced thereby facilitating retraction of the needle back into the passage. In the prior embodiments, such as those shown in
In the exemplary embodiments, the introducer tip will be joined to the central member by a transition region, usually a region which tapers in the distal direction from the distal end of the central member toward the proximal end of the introducer tip, e.g. a conical transition zone. This tapered or conical transition region facilitates advancement of the central member into tissue following the initial introduction of the introducer tip. In other exemplary aspects of the present invention, the introducer tip may have an axial channel in the surface which is disposed alongside the needle advancement path. Thus, the needle may be advanced through the channel to further enhance stabilization of the needle. In a still further exemplary aspect of the needle electrode deployment device, an exit port of the electrode advancement passage will have a rounded peripheral edge to still further decrease focal stress and the chance of binding and damage to the needle as the needle is retracted back within the electrode advancement passage. Finally, while the needle electrode deployment device may be used with only a single central needle, as described thus far, usually it will be combined with a plurality of laterally deployable needle electrodes as described in conjunction with the previous embodiments of the present invention.
In addition to the radially offset spike just described the spike or other introducer tip of the present invention may take a variety of other forms. For example, the spike may have a chamfered surface which provides a tapered profile extending from the distal end of the central member to the distal tip of the spike or introducer tip. The chamfered surface will have an opening or port which allows advancement of the central electrode therethrough. Usually, the port or opening will comprise an electrode transition cavity which can have a generally spherical, conical, or ovoid shape which extends from the electrode deployment port of the central lumen in the central member. The electrode deployment port itself may be in the form of a slot, circle, oval, or have a variety of other configurations.
In a further embodiment, the introducer tip may comprise a plurality of axially aligned spikes extending from the distal end of the central member, typically from the periphery of the distal end. In this way, the central electrode may be advanced distally through a protected region defined within the plurality of spikes.
Finally, in a further embodiment, the introducer tip or spike may be solid and fixedly attached to the distal end of the central member. By electrically isolating a portion of the fixed spike, the spike may act as a central electrode and replace the axially reciprocated central electrode of the other embodiments described herein.
The various embodiments described above significantly increase the number of times that the needle electrode deployment device may be used in a single procedure on a patient. Repeated deployment of the central electrode can often cause undue stress and wear, often resulting from interference and interaction with the exit port from the central electrode lumen or passageway, both as the central electrode is deployed and refracted as well as when the device is angled and manipulated in tissue during use. The particular needle exit configurations described above can lessen the stress and increase the deployable electrode life. In the case of the fixed center electrode, the requirement of repeated center electrode deployment is eliminated altogether.
The present invention provides electrode deployment structures comprising needle electrode deployment shafts capable of reciprocatably deploying a plurality of needle electrodes into solid tissue. The needle electrode deployment shafts will comprise a central member having a proximal end, a distal end, and a longitudinal axis therebetween. Typically, the central member will have a distal end which is configured to permit self-penetration, e.g. the central member may itself be a needle having a sharpened or chamfered tip which permits the central member to be advanced into tissue by simply pushing. In other embodiments, the central member could comprise a hollow tubular body, commonly referred to as a cannula, having a needle or stylet removably received within a central lumen thereof. The cannula could then be introduced by placing the stylet with its sharpened tip extending from the distal end of the cannula and pushing the assembly of the cannula and stylet into tissue. The stylet could then be removed, leaving the lumen in place for other purposes. In a further alternative, the central member could have a tip with an electrode, optical element, abrasive surface, or otherwise configured to permit energy-mediated advancement of the distal tip through tissue.
The needle electrodes will typically be hollow core needles, tubes, or wires which have sufficient column strength so that they may be pushed from the central member into tissue. Typically, the needle electrodes will have sharpened tips but alternatively they could be configured with electrodes or other elements to permit energy-mediated advancement. The needle electrodes will typically be pre-shaped in a straight configuration but in other embodiments could be pre-shaped curved, helical, or have other geometries. The needle electrodes will also usually be elastic, typically being formed from an elastic metal, such as spring stainless steel, nitinol, eligiloy, or other superelastic material. By “pre-shaped” it is meant that the needles have an elastic memory of the desired straight or other configuration. In other embodiments, however, the needle electrodes could be formed from a malleable metal, such as various surgical steels where the needle electrodes may undergo plastic deformation as they are advanced over the ramp portion of the channel as described below.
The needle deployment shaft will usually be intended for deploying the plurality of needles into tissue in order to deliver radiofrequency or other electrical energy for treating the tissue. Treatments will usually comprise heating, more usually comprising the delivery of radiofrequency energy into the tissue via a monopolar or bipolar protocol. By monopolar, it is meant that the plurality of needle electrodes and optionally the central member will be connected to one pole of a radiofrequency generator while the other pole will be connected to a neutral or common electrode which is attached to the patient via a pad or other relatively large area electrical contact surface. By bipolar it is meant that at least some of the plurality of needle electrodes and/or the central member are connected to opposite poles of the radiofrequency power supply so that the radiofrequency current is concentrated between the oppositely connected electrodes and/or central member.
The needle electrode deployment shaft is particularly suitable for deploying the plurality of needles in solid tissues, such as uterine tissue, breast tissue, liver tissue, fibrous tissue, kidney tissue, pancreatic tissue, prostate tissue, brain tissue, skeletal muscle, and the like, for the delivery of energy to ablate tumors and other diseased portions of the tissue. In other instances, however, the needle electrode deployment shafts could be useful for deploying the plurality of needles for aesthetic treatments, such as collagen tightening, fat (adipose) tissue treatment, and the like.
Referring now to
In one specific aspect of the invention, the central member or main needle shaft 170 has a tip 180 which has a reduced diameter relative to the proximal portions of the central member. In particular, the tip 180 is disposed coaxially along the same axis as the remainder of the central member 170 but is stepped-down in diameter, typically over a conical transition region 181. The tip 180 will terminate in a sharpened distal end 183 which is configured to facilitate advancement of the central member through tissue. Optionally, the entire central member 170 may have a central lumen or passage therethrough with a distal opening 185 illustrated in
The structure of tip 180 is advantageous since it reduces the insertion force required to advance the central member 170 through tissue. It will be appreciated that the smaller diameter of the tip 180 will require less force to be introduced into the tissue and will prepare a pilot tract through the tissue. The larger diameter proximal portion of the central member 170 may enter the established tissue tract with the force of entry being reduced by the conical transition region 181. By providing a proximal portion of the central member with a larger diameter, there is increased area and volume for forming the needle advancement channels 102 as described in more detail below.
The needle advancement channels 102 may be formed in either of two basic configurations. The first of these configurations is illustrated in
While suitable for many particular applications, the use of axially aligned needle electrode advancement channels 102 is disadvantageous since it has a limited change in radial depth through which the needle can be bent. By employing arcuate or spiral needle paths, as shown in
The differences between the straight, simple curved or arcuate, and spiral needle paths are illustrated in
A needle ramp 204 having a simple curved or arcuate shape in a cylindrical shaft 206 is illustrated. The initial depth di of the ramp 204 may be the same as that in the straight or axial channel 200, and the final depth will be zero in both cases. Thus, while the change in depth will be the same, by curving the needle path or channel 204, the total length of travel of the needle through which it is bent outwardly (away from the central axis of the central member) is increased, thus increasing the needle exit angle for a given needle strain.
The radial component of the needle path or channel, and thus the needle angle, can be increased still further by forming a spiral path 208, as illustrated in
The needle electrode deployment structures as just described may be employed in a variety of delivery systems for positioning the central shaft in a body and advancing the individual needle electrodes into tissue. Most simply, the central member or main needle shaft can be fixedly attached to a handle with a trigger or lever mechanism coupled to the needle electrodes to selectively advance and retract them within the needle advancement channels 102. In a particular use, the needle electrode deployment structures 100 may be combined in an ablation device having an on-board imaging transducer as described in application Ser. No. 61/091,708, the full disclosure of which has previously been incorporated herein by reference. The details of such structures are provided below.
Referring to
The handle 122 will also include a delivery needle electrode deployment mechanism 130 which includes a first slide subassembly 132 and a second slide subassembly 134. The handle will usually further include a port 136 at its proximal end. Port 136 allows introduction of an ultrasonic or other imaging core, where the imaging core has an imaging array 138, typically an ultrasonic imaging array as described in detail in copending application Ser. Nos. 11/620,594; 11/620,569; and 11/564,164, the full disclosures of which are incorporated herein by reference. The proximal end of the handle will also allow electrical connections to be made to the needle electrode array. Additionally, the distal end of the handle will usually provide a standard luer connection for the infusion of non-conductive coupling fluids.
Referring now to
The first slide subassembly 132 comprises a reciprocating carriage 166 having a coupling 168 attached to a proximal end of the needle 170. The carriage 166 may be axially advanced and retracted by manually pressing buttons 172 to disengage pins 174 (
Referring now in particular to
The use of the imaging and therapeutic delivery system 110 of the present invention is illustrated in
Referring now to
In contrast to the previous embodiments, the needle electrode deployment device 200 includes an introducer tip or spike 210 terminating with a faceted cutting tip 212, similar to a trocar cutting tip, to facilitate introduction into tissue as the central member is manually or otherwise advanced in a distal direction through uterine or other solid tissue. The axially aligned electrode advancement passage 205 terminates in a central electrode deployment port 214 which is proximally retracted from the faceted cutting tip 212 of the spike 210, typically by a distance in the range from 1 mm to 10 mm. Preferably, an axial channel or groove 216 is formed along an inner surface of the spike 210, which channel or groove will act as a guide as a central electrode 230 (
The spike 210 has a cross-sectional area which is significantly less than the cross-sectional area of the central member 202. In the illustrated embodiment, the cross-sectional area of the introducer tip 210 is about 25% of the cross-sectional area of the central member 202, but the percentage of decrease can vary within the ranges set forth above in the Summary of the Invention. Usually, the diameter of the central member will be in the range from 0.75 mm to 3 mm, e.g. having a circular cross-section. The cross-sectional area of the introducer tip will usually be in the range from 0.25 mm2 to 5 mm2.
By proximally retracting and radially offsetting the axis of the spike 210 relative to the central electrode port 214 and the central axis of the central member 202, an improved and stabilized geometry is provided for deploying central electrode 230, as illustrated in
After the device 200 has been introduced into tissue and the central electrode 230 and optionally peripheral electrodes (not shown) are advanced into the tissue, the central member 202 can sometimes become misaligned so that the electrode 230 is stressed and bent at the region where it exits from the axially aligned electrode advancement passage 205, as shown in
Referring now to
Referring now to
The embodiment of
Another embodiment of a central member 340 comprises a single spike 342 attached to the distal end of the center member. The single spike 342 will preferably be electrically isolated so that it can be connected to a wire to provide RF or other current for treatment. The single spike 342 will preferably terminate in a sharpened tip, such as trocar tip 344 to permit self introduction of the central member 340 through tissue. The central member 340 will preferably include a plurality of peripheral electrode deployment channels 346, which channels are formed generally as described for previous embodiments.
While the above is a complete description of the preferred embodiments of the invention, various alternatives, modifications, and equivalents may be used. Therefore, the above description should not be taken as limiting the scope of the invention which is defined by the appended claims.
This application is a continuation of U.S. patent application Ser. No. 16/417,193, filed May 20, 2019, now U.S. Pat. No. 11,564,735; which is a continuation of U.S. patent application Ser. No. 13/589,956, filed Aug. 20, 2012, now U.S. Pat. No. 10,321,951; which is a divisional of Ser. No. 12/712,969, filed Feb. 25, 2010, now U.S. Pat. No. 8,262,574; which claims the benefit of provisional application No. 61/156,270, filed on Feb. 27, 2009; the full disclosures of which are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
4802487 | Martin et al. | Feb 1989 | A |
4936281 | Stasz | Jun 1990 | A |
5372587 | Hammerslag et al. | Dec 1994 | A |
5456689 | Kresch et al. | Oct 1995 | A |
5469853 | Law et al. | Nov 1995 | A |
5471988 | Fujio et al. | Dec 1995 | A |
5492126 | Hennige et al. | Feb 1996 | A |
5527331 | Kresch et al. | Jun 1996 | A |
5607389 | Edwards et al. | Mar 1997 | A |
5662664 | Gordon et al. | Sep 1997 | A |
5666954 | Chapelon et al. | Sep 1997 | A |
5697897 | Buchholtz et al. | Dec 1997 | A |
5730752 | Alden et al. | Mar 1998 | A |
5741287 | Alden et al. | Apr 1998 | A |
5752518 | McGee et al. | May 1998 | A |
5769880 | Truckai et al. | Jun 1998 | A |
5860974 | Abele et al. | Jan 1999 | A |
5863294 | Alden | Jan 1999 | A |
5873828 | Fujio et al. | Feb 1999 | A |
5876340 | Tu et al. | Mar 1999 | A |
5876399 | Chia et al. | Mar 1999 | A |
5891137 | Chia et al. | Apr 1999 | A |
5906615 | Thompson | May 1999 | A |
5908385 | Chechelski et al. | Jun 1999 | A |
5916198 | Dillow | Jun 1999 | A |
5957941 | Ream | Sep 1999 | A |
5964740 | Ouchi | Oct 1999 | A |
5979452 | Fogarty et al. | Nov 1999 | A |
5979453 | Savage et al. | Nov 1999 | A |
5984942 | Alden et al. | Nov 1999 | A |
6002968 | Edwards | Dec 1999 | A |
6007499 | Martin et al. | Dec 1999 | A |
6032673 | Savage et al. | Mar 2000 | A |
6039748 | Savage et al. | Mar 2000 | A |
6050992 | Nichols | Apr 2000 | A |
6059766 | Greff | May 2000 | A |
6077257 | Edwards et al. | Jun 2000 | A |
6083169 | Hansen | Jul 2000 | A |
6126665 | Yoon | Oct 2000 | A |
6141577 | Rolland et al. | Oct 2000 | A |
6146378 | Mikus et al. | Nov 2000 | A |
6158250 | Tibbals, Jr. et al. | Dec 2000 | A |
6171249 | Chin et al. | Jan 2001 | B1 |
6190383 | Schmaltz et al. | Feb 2001 | B1 |
6193714 | McGaffigan et al. | Feb 2001 | B1 |
6211153 | Garnick et al. | Apr 2001 | B1 |
6238336 | Ouchi | May 2001 | B1 |
6254601 | Burbank et al. | Jul 2001 | B1 |
6280441 | Ryan | Aug 2001 | B1 |
6296639 | Truckai et al. | Oct 2001 | B1 |
6306097 | Park et al. | Oct 2001 | B1 |
6306129 | Little et al. | Oct 2001 | B1 |
6315741 | Martin et al. | Nov 2001 | B1 |
6379348 | Onik | Apr 2002 | B1 |
6405732 | Edwards et al. | Jun 2002 | B1 |
6419648 | Vitek et al. | Jul 2002 | B1 |
6419653 | Edwards et al. | Jul 2002 | B2 |
6419673 | Edwards et al. | Jul 2002 | B1 |
6425867 | Vaezy et al. | Jul 2002 | B1 |
6432067 | Martin et al. | Aug 2002 | B1 |
6461296 | Desai | Oct 2002 | B1 |
6463331 | Edwards | Oct 2002 | B1 |
6482203 | Paddock et al. | Nov 2002 | B2 |
6485413 | Boppart et al. | Nov 2002 | B1 |
6506154 | Ezion et al. | Jan 2003 | B1 |
6506156 | Jones et al. | Jan 2003 | B1 |
6506171 | Vitek et al. | Jan 2003 | B1 |
6507747 | Gowda et al. | Jan 2003 | B1 |
6508815 | Strul et al. | Jan 2003 | B1 |
6522142 | Freundlich | Feb 2003 | B1 |
6540677 | Angelsen et al. | Apr 2003 | B1 |
6543272 | Vitek | Apr 2003 | B1 |
6550482 | Burbank et al. | Apr 2003 | B1 |
6554780 | Sampson et al. | Apr 2003 | B1 |
6554801 | Steward et al. | Apr 2003 | B1 |
6559644 | Froundlich et al. | May 2003 | B2 |
6569159 | Edwards et al. | May 2003 | B1 |
6579298 | Bruneau et al. | Jun 2003 | B1 |
6589237 | Woloszko et al. | Jul 2003 | B2 |
6602251 | Burbank et al. | Aug 2003 | B2 |
6610054 | Edwards et al. | Aug 2003 | B1 |
6612988 | Maor et al. | Sep 2003 | B2 |
6613004 | Vitek et al. | Sep 2003 | B1 |
6613005 | Friedman et al. | Sep 2003 | B1 |
6623481 | Garbagnati et al. | Sep 2003 | B1 |
6626854 | Friedman et al. | Sep 2003 | B2 |
6626855 | Weng et al. | Sep 2003 | B1 |
6632193 | Davison et al. | Oct 2003 | B1 |
6635055 | Cronin | Oct 2003 | B1 |
6635065 | Burbank et al. | Oct 2003 | B2 |
6638275 | McGaffigan et al. | Oct 2003 | B1 |
6638286 | Burbank et al. | Oct 2003 | B1 |
6645162 | Friedman et al. | Nov 2003 | B2 |
6645202 | Pless et al. | Nov 2003 | B1 |
6652516 | Gough | Nov 2003 | B1 |
6660002 | Edwards et al. | Dec 2003 | B1 |
6660024 | Flaherty et al. | Dec 2003 | B1 |
6663624 | Edwards et al. | Dec 2003 | B2 |
6663626 | Truckai et al. | Dec 2003 | B2 |
6666833 | Friedman et al. | Dec 2003 | B1 |
6669643 | Dubinsky | Dec 2003 | B1 |
6679855 | Horn et al. | Jan 2004 | B2 |
6685639 | Wang et al. | Feb 2004 | B1 |
6689128 | Sliwa et al. | Feb 2004 | B2 |
6692490 | Edwards | Feb 2004 | B1 |
6701931 | Sliwa et al. | Mar 2004 | B2 |
6705994 | Vortman et al. | Mar 2004 | B2 |
6712815 | Sampson et al. | Mar 2004 | B2 |
6716184 | Vaezy et al. | Apr 2004 | B2 |
6719755 | Sliwa et al. | Apr 2004 | B2 |
6728571 | Barbato | Apr 2004 | B1 |
6730081 | Desai | May 2004 | B1 |
6735461 | Vitek et al. | May 2004 | B2 |
6743184 | Sampson et al. | Jun 2004 | B2 |
6746447 | Davison et al. | Jun 2004 | B2 |
6764488 | Burbank et al. | Jul 2004 | B1 |
6773431 | Eggers et al. | Aug 2004 | B2 |
6790180 | Vitek | Sep 2004 | B2 |
6805128 | Pless et al. | Oct 2004 | B1 |
6805129 | Pless et al. | Oct 2004 | B1 |
6813520 | Truckai et al. | Nov 2004 | B2 |
6832996 | Woloszko et al. | Dec 2004 | B2 |
6837887 | Woloszko et al. | Jan 2005 | B2 |
6837888 | Ciarrocca et al. | Jan 2005 | B2 |
6840935 | Lee | Jan 2005 | B2 |
6899712 | Moutafis et al. | May 2005 | B2 |
6921398 | Carmel et al. | Jul 2005 | B2 |
6936048 | Hurst | Aug 2005 | B2 |
6944490 | Chow | Sep 2005 | B1 |
6969354 | Marian | Nov 2005 | B1 |
7101387 | Garabedian | Sep 2006 | B2 |
7160296 | Pearson et al. | Jan 2007 | B2 |
7229401 | Kindlein | Jun 2007 | B2 |
7247141 | Makin et al. | Jul 2007 | B2 |
7387628 | Behl et al. | Jun 2008 | B1 |
7517346 | Sloan et al. | Apr 2009 | B2 |
7874986 | Deckman et al. | Jan 2011 | B2 |
7963941 | Wilk | Jun 2011 | B2 |
8080009 | Lee et al. | Dec 2011 | B2 |
8157741 | Hirota | Apr 2012 | B2 |
8157745 | Schoot | Apr 2012 | B2 |
8216231 | Behl et al. | Jul 2012 | B2 |
8221321 | McMorrow et al. | Jul 2012 | B2 |
8262574 | Placek et al. | Sep 2012 | B2 |
8287485 | Kimura et al. | Oct 2012 | B2 |
8377041 | Frassica et al. | Feb 2013 | B2 |
8469893 | Chiang et al. | Jun 2013 | B2 |
8512330 | Epstein et al. | Aug 2013 | B2 |
8512333 | Epstein et al. | Aug 2013 | B2 |
8540634 | Bruce et al. | Sep 2013 | B2 |
8585598 | Razzaque et al. | Nov 2013 | B2 |
8622911 | Hossack et al. | Jan 2014 | B2 |
8663130 | Neubach et al. | Mar 2014 | B2 |
8718339 | Tonomura et al. | May 2014 | B2 |
8814796 | Martin et al. | Aug 2014 | B2 |
9089287 | Sliwa et al. | Jul 2015 | B2 |
9198707 | McKay et al. | Dec 2015 | B2 |
9198719 | Murdeshwar et al. | Dec 2015 | B2 |
9247925 | Havel et al. | Feb 2016 | B2 |
9357977 | Grossman | Jun 2016 | B2 |
9439627 | Case et al. | Sep 2016 | B2 |
9510898 | Epstein et al. | Dec 2016 | B2 |
9516996 | Diolaiti et al. | Dec 2016 | B2 |
10321951 | Placek et al. | Jun 2019 | B2 |
11564735 | Placek et al. | Jan 2023 | B2 |
20020068871 | Mendlein et al. | Jun 2002 | A1 |
20020077550 | Rabiner et al. | Jun 2002 | A1 |
20020183735 | Edwards et al. | Dec 2002 | A1 |
20030014046 | Edwards et al. | Jan 2003 | A1 |
20030032896 | Bosley et al. | Feb 2003 | A1 |
20030114732 | Webler et al. | Jun 2003 | A1 |
20030130575 | Desai | Jul 2003 | A1 |
20030130655 | Woloszko et al. | Jul 2003 | A1 |
20030195420 | Mendlein et al. | Oct 2003 | A1 |
20030195496 | Maguire et al. | Oct 2003 | A1 |
20030199472 | Al-Hendy et al. | Oct 2003 | A1 |
20030216725 | Woloszko et al. | Nov 2003 | A1 |
20030216759 | Burbank et al. | Nov 2003 | A1 |
20040002699 | Ryan et al. | Jan 2004 | A1 |
20040030268 | Weng et al. | Feb 2004 | A1 |
20040054366 | Davison et al. | Mar 2004 | A1 |
20040120668 | Loeb | Jun 2004 | A1 |
20040153057 | Davison | Aug 2004 | A1 |
20040175399 | Schiffman | Sep 2004 | A1 |
20040176760 | Qiu | Sep 2004 | A1 |
20040193028 | Jones et al. | Sep 2004 | A1 |
20040215182 | Lee | Oct 2004 | A1 |
20040230190 | Dahla et al. | Nov 2004 | A1 |
20040254572 | McIntyre et al. | Dec 2004 | A1 |
20050038340 | Vaezy et al. | Feb 2005 | A1 |
20050107781 | Ostrovsky et al. | May 2005 | A1 |
20050124882 | Ladabaum et al. | Jun 2005 | A1 |
20050149013 | Lee | Jul 2005 | A1 |
20050215990 | Govari | Sep 2005 | A1 |
20050216039 | Lederman | Sep 2005 | A1 |
20050228288 | Hurst | Oct 2005 | A1 |
20050255039 | Desai | Nov 2005 | A1 |
20050256405 | Makin et al. | Nov 2005 | A1 |
20060010207 | Akerman et al. | Jan 2006 | A1 |
20060058680 | Solomon | Mar 2006 | A1 |
20060184049 | Tsujita | Aug 2006 | A1 |
20060189972 | Grossman | Aug 2006 | A1 |
20070006215 | Epstein | Jan 2007 | A1 |
20070083082 | Kiser et al. | Apr 2007 | A1 |
20070112306 | Agnew | May 2007 | A1 |
20070161905 | Munrow | Jul 2007 | A1 |
20070249939 | Gerbi et al. | Oct 2007 | A1 |
20080033493 | Deckman et al. | Feb 2008 | A1 |
20080188916 | Jones et al. | Aug 2008 | A1 |
20080228081 | Becker et al. | Sep 2008 | A1 |
20090043295 | Arnal et al. | Feb 2009 | A1 |
20100262133 | Hoey et al. | Oct 2010 | A1 |
20120165813 | Lee et al. | Jun 2012 | A1 |
20120209115 | Tonomura | Aug 2012 | A1 |
20120277737 | Curley | Nov 2012 | A1 |
20130281863 | Chiang et al. | Oct 2013 | A1 |
20130317366 | Hirayama et al. | Nov 2013 | A1 |
20140180273 | Nair | Jun 2014 | A1 |
20140276081 | Tegels | Sep 2014 | A1 |
20150150497 | Goldchmit | Jun 2015 | A1 |
20150173592 | Leeflang et al. | Jun 2015 | A1 |
20150257779 | Sinelnikov et al. | Sep 2015 | A1 |
20160151041 | Lee et al. | Jun 2016 | A1 |
20160278740 | Negrila et al. | Sep 2016 | A1 |
20160310042 | Kesten et al. | Oct 2016 | A1 |
Number | Date | Country |
---|---|---|
WO-9717105 | May 1997 | WO |
WO-9811834 | Mar 1998 | WO |
WO-9814169 | Apr 1998 | WO |
WO-9943366 | Sep 1999 | WO |
WO-0000098 | Jan 2000 | WO |
WO-0180723 | Nov 2001 | WO |
WO-0195819 | Dec 2001 | WO |
WO-0211639 | Feb 2002 | WO |
WO-0180723 | Apr 2002 | WO |
WO-03005882 | Jan 2003 | WO |
WO-03065908 | Aug 2003 | WO |
WO-03005882 | Nov 2003 | WO |
WO-2004002293 | Jan 2004 | WO |
WO-2004002550 | Jan 2004 | WO |
WO-2004020011 | Mar 2004 | WO |
WO-2004035110 | Apr 2004 | WO |
WO-2004035110 | Jun 2004 | WO |
WO-2004058328 | Jul 2004 | WO |
WO-2004064658 | Aug 2004 | WO |
WO-2004002550 | Oct 2004 | WO |
WO-2004058328 | Oct 2004 | WO |
WO-2004002293 | Jul 2005 | WO |
WO-2007005830 | Jan 2007 | WO |
WO-2007144004 | Dec 2007 | WO |
WO-2010099481 | Sep 2010 | WO |
Entry |
---|
Bergamini, et al. Laparoscopic Radiofrequency Thermal Ablation: A New Approach to Symptomatic Uterine Myomas. Am. J. Obstetrics and Gynecology (2005) 192: 768-73. |
CNN.com Health Women. Experimental technique uses lasers to shrink uterine fibroids. Nov. 28, 2000. |
European search report and search opinion dated Jul. 28, 2015 for EP Application No. 15163596.8. |
European search report dated Jul. 6, 2012 for EP Application No. 10746938.9. |
Hindley, et al. MRI guidance of focused ultrasound therapy of uterine fibroids: Early results. American Journal of Roentgenology, 2004, 183(6): 1173-1719. |
International search report and written opinion dated Apr. 26, 2010 for PCT/US2010/025647. |
Kanaoka, et al. Microwave endometrial ablation at a frequency of 2.45 Ghz. A pilot study. J Reprod Med. Jun. 2001; 46(60): 559-63. |
Law, et al. Magnetic resonance-guided percutaneous laser ablation of uterine fibroids. J Magn Reson Imaging, Oct. 2000; 12(4):565-70. |
Liu, et al. Catheter-Based Intraluminal Sonography. J. Ultrasound Med., 2004, 23:145-160. |
Lumsden et al., Clinical presentation of Uterine Fibroids, Baillieres Clinical Obstetrics & Gynaecology. Jun. 1998;12(2):177-95. |
Mogami, et al. Usefulness of MR-guided percutaneous cryotherapy. Med. Imaging Technol. 2004, 22(3): 131-6. (English abstract). |
MSNBC OnLine Articles, About Us: Articles; “Intrauerine Fibroids Can Now Be Treated Nonsurgically” http://www.fibroids.com/news-blog/2004/08/intrauterine-fibroids-can-now-be-treated-nonsurgically/ Aug. 23, 2004. |
Notice of allowance dated Jun. 7, 2012 for U.S. Appl. No. 12/712,969. |
Office action dated Jan. 21, 2021 for U.S. Appl. No. 16/417,193. |
Office action dated Feb. 1, 2012 for U.S. Appl. No. 12/712,969. |
Office Action dated Feb. 1, 2017 for U.S. Appl. No. 13/589,956. |
Office action dated Apr. 9, 2015 for U.S. Appl. No. 13/589,956. |
Office action dated Dec. 26, 2014 for U.S. Appl. No. 13/589,956. |
Okamura, et al. Force Modeling for Needle Insertion into Soft Tissue. IEEE Transactions on Biomedical Engineering, Oct. 2001, 10 (51): 1707-1716. |
RSNA 2000 Explore News Release. Lasers Liquify Uterine Fibroid Tumors. 11:30 a.m. CST, Monday, Nov. 27, 2000. |
Senoh, et al. Saline Infusion Contrast Intrauterine Sonographic Assessment of the Endometrium with High-Frequency, Real-Time Miniature Transducer Normal Menstrual Cycle: a Preliminary Report. Human Reproduction, 14 (10): 2600-2603, 1999. |
U.S. Appl. No. 16/417,193 Notice of Allowance dated Sep. 23, 2022. |
U.S. Appl. No. 13/589,956 Office Action dated Apr. 7, 2016. |
U.S. Appl. No. 16/417,193 Office Action dated Jul. 15, 2021. |
U.S. Appl. No. 16/417,193 Office Action dated Mar. 15, 2022. |
U.S. Appl. No. 13/589,956 Notice of Allowance dated Feb. 5, 2019. |
Vascular and Interventional Radiology, SRSC; Nonsurgical Treatment of Uterine Fibroids. Available at http://www.drfibroid.com/treatment.htm. Accessed Apr. 11, 2011. |
Websand, Inc., New treatment options for fibroid tumors, Copyright 2002 by WebSand, Inc. |
Number | Date | Country | |
---|---|---|---|
20230123386 A1 | Apr 2023 | US |
Number | Date | Country | |
---|---|---|---|
61156270 | Feb 2009 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12712969 | Feb 2010 | US |
Child | 13589956 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16417193 | May 2019 | US |
Child | 18085443 | US | |
Parent | 13589956 | Aug 2012 | US |
Child | 16417193 | US |